Objective Rapid detection of serum anti-ganglioside antibodies in Guillain-Barre syndrome (GBS) could facilitate early diagnosis and early initiation of treatment, which might shorten the term of illness and reduce sequelae. Weexaminedserum anti-ganglioside antibodies in patients with GBSusing the latex agglutination assay developed by Alaedini and Latov (J Immunoassay 21:
Introduction
Serum anti-ganglioside antibodies have been assayed by thin-layer chromatography (TLC) or enzyme-linked immunosorbent assay (ELISA) in patients with Guillain-Barre syndrome (GBS), and its variant Miller Fisher syndrome (MFS) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . As a result of this prevalence, it is known that some types of anti-ganglioside antibodies are specifically linked with the antecedent events or clinical features in GBS. Serum IgG anti-GMl antibodies with or without anti-GDIb antibodies, which are often present after Campylobacter jejuni enteritis (3, (13) (14) (15) , sometimes cause acute motor axonal (AMAN) or motor and sensory axonal neuropathy (AMSAN) (16, 17) . IgM anti-GM2 antibodies occur in patients, frequently associated with facial palsy and sensory neuropathy, with an antecedent CMVinfection (9, 18, 19) . IgG anti-GQlb antibodies frequently occur in patients with acute ophthalmoplegia following GBS, MFS, or Bickerstaff's brainstem encephalitis (5, (20) (21) (22) (23) .
In particular, around 90% of patients with MFS have these antibodies in the acute stage of the illness (21, 24) . Therefore, the detection of serum anti-ganglioside antibodies suggests the possibility that a patient has GBS,or one of its variants, including MFSor Bickerstaff's brainstem encephalitis. The assaying of anti-ganglioside antibodies seems
Rapid Assay of Anti-ganglioside Antibody immunological treatment with plasmapheresis or intravenous gammaglobulinscan shorten the term of illness and reduce sequelae (25, 26) , early diagnosis by means of a rapid assay for anti-ganglioside antibodies would be useful for determining the treatment. Recently, Alaedini and Latov reported a rapid agglutination assay for anti-GMl antibodies (27) . We examined serum anti-ganglioside antibodies in patients with GBSusing this latex agglutination assay, with some modifications, and compared the results with ELISA.
For editorial comment, see p 457.
Materials and Methods

ELISA
Sera from 147 patients with GBSwere collected in our hospital and other institutions in Japan between April 1996 and March 2001. All patients were evaluated according to the established diagnostic criteria for GBS (28) . Sera from 75 healthy adults were also collected as controls. The sera were all frozen at -30°C until use. Weexamined serum IgM and IgG anti-GMl, GDlb, GQlb, GDla, GTlb, GM2 and GTla antibodies by ELISA according to the previous method (29) had IgG or IgM anti-GMl, GDlb, GQlb or GM2 antibodies. One patient had only IgG anti-GDla antibodies and the other only IgG anti-GTla antibodies. All patients with anti-GTlb antibodies had other kinds of antiganglioside antibodies. IgG anti-GMl, GDlb or GQlb antibodies, or IgM anti-GM2 antibodies, as major antiganglioside antibodies, were detected in 75 patients, including 29 with 2 kinds of these antibodies ( Table 2 ). The titers of these major anti-ganglioside antibodies were distributed between 1 : 100 and 1 : 51,200 ( Fig. 1 and Table 2 ).
Agglutination assay
Agglutination was strong in the sera of which the IgM or IgG titers of anti-GMl, GDlb, GQlb or GM2 antibodies were found to be 1 : 6,400 or more than 1 : 6,400 on previous ELISAexcept for 2 samples, but weak or absent in sera with titers of I : 3,200 (Figs. 2 and 3, and Table 2 ). Agglutination was absent in sera of which the anti-ganglioside antibody titers were less than 1 : 3,200 on ELISA. With the serum of which the ELISA titer of IgG anti-GMl antibodies was 1 : 51,200, the agglutination was greatly diminished in the serum diluted 32 times (Fig. 4) . Overall, agglutination was detected in 18 (24.0%) of 75 GBS patients with IgG anti-GMl, GDlb or GQlb, or IgM anti-GM2 antibodies on ELISA ( 
Discussion
There have only been a few reports demonstrating the frequency of serum anti-ganglioside antibodies in GBSpatients who had been tested by ELISAfor more than 5 species of gangliosides, including at least anti-GMl, GDlb, GQlb, GDla and GM2 (12, 17, 30) . In the largest study, Miyazaki et al showed that 241 (54.2%) of 445 GBSpatients had at 1:25,600 à"à" j j à" I 1:12,800 -à"à"à"à"à" : à" : à" j 1:6,400 -i à"à"à"à" : à"à"à"à"à" : à"à" 1:3,200 à"à" j à" j à" j 1:1,600-I à"à"à" j à"à"à" j à"à" 1:800 -à"à" ! à"à"à"à"à"à"à"à"à" | à" | à"à" 1:400-à"à"à"à"à"à"à"à" j à"à"à"à"à"à"à" : ##### à" à"à"à"à" 1:200* à"à"à"à" j à"à"à"à"à"à"à"à"à" j à"à"à"à"à" j à"à"à"#à"
Anti-GMl antibody Anti-GDlb antibody Anti-GQlb antibody Anti-GM2 antibody least one of the anti-ganglioside antibodies (12) . In the present study, anti-GMl, GDlb, GQlb, GDla, GTlb, GM2 and GTla antibodies were seen in 58.5% of the 147 GBS patients. The levels of major serum anti-ganglioside antibodies in GBS patients were 27.9% of anti-GMl antibodies (19 GBSpatients, accounting for 97.7% of all patients with antiganglioside antibodies. Anti-GDla, GTlb and GTla antibodies can rarely occur independently, as shown from our results. In addition, among the recent 35 patients with GBS for whomwe measured anti-GalNAc-GDla antibodies, all 6 patients associated with anti-GalNAc-GDla antibodies also had antibodies to GM1,GQlb or GM2.Serum antibodies to GMlband LM1 are also rarely detected independently (10, ll) . Therefore, it might be less common to detect antiganglioside antibodies that do not cross-react with GM1, GDlb, GQlb or GM2.
Although examination of anti-ganglioside antibodies has been more routine for the diagnosis and more meaningful for investigation of the pathogenesis in patients with GBSand its variants, ELISAis bothersome due to the manyprocesses including coating of wells with ganglioside, incubation of serum, usually overnight, reaction with enzyme-conjugated antibodies to human immunoglobulins, development with a substrate, and finally measurement of absorbance. TLC, which has also been a commonlyused method for the detection of anti-ganglioside antibodies, requires more complicated processes and higher technical skill. The establishment of a more convenient and rapid method for anti-ganglioside antibodies is an obvious necessity, because the detection of these antibodies facilitates diagnosis and allows the early start of treatment in patients with GBS. In comparison with ELISA and TLC, the latex agglutination assay is very convenient, and only a few minutes are needed to visualize the reaction without any second antibodies or developing material when ganglioside-coated latex beads are prepared in advance.
In the present study, we were able to detect anti-GMl, GDlb, GQlb and GM2antibodies with this agglutination assay. However, we only observed a positive reaction in sera with titers of at least 1 : 6,400 of anti-ganglioside antibodies on ELISA. We could detect anti-GMl, GDlb, GQlb and GM2antibodies in only 24% of the positive patients as compared with ELISA. This means that the sensitivity of this agglutination assay is much lower than that of ELISA. Recently, Alaedini et al detected anti-ganglioside antibodies using crude bovine gangliosides by means of their latex agglutination assay in 21 of 40 (53%) patients with GBS, including acute inflammatory demyelinating polyneuropathy, AMAN, AMSANand MFS, but in 43% with their ELISA for anti-GMl, GM2, GDla, GDlb, GTlb and GQlb (31) . Although in the total extract it is unknown with which ganglioside the sera react, the positive rate of antiganglioside antibodies in their agglutination assay was 123.3% as compared with their ELISA. They explain that this high rate is due to the presence of antibodies to minor ganglioside species in the total antigenic extract and that the agglutination assay measures a more physiological interaction than in the case of ELISA. Excluding MFS, Alaedini et al detected anti-ganglioside antibodies in 50% of GBS pa-tients with their agglutination assay and only in 39% of GBS patients with their ELISA; this frequency is much lower than those of a recent large study by Miyazaki et al (12) and in the present study. The sensitivity of their ELISAcould be lower than our ELISA. Because serum antibodies only to minor gangliosides might rarely occur, as mentioned above, it is possible that Alaedini et al mayhave detected nearly all of the major anti-ganglioside antibodies with their agglutination assay. It is unknownwhy there is a large discrepancy between the results of Alaedini et al using the total ganglioside extract and ours using purified gangliosides. The total ganglioside extract could contain other glycolipids and unknownsubstances as impurities, and therefore agglutination could have been promoted by some impurities in their assay. It is important to detect serum anti-ganglioside antibodies rapidly in patients with GBS and its variants for immediate treatment. Wesuggest that a latex agglutination assay is a very convenient and rapid method for examining serum antibodies to gangliosides. More modifications are needed to increase the sensitivity of our agglutination assay.
